Search research articles
Contact Us
Filters
Showing results (21-30 of 283) with videos related to
Page
of 29
Sort By:
Journal of Gastroenterology
|
November 5, 2018
Antimicrobial proteins: intestinal guards to protect against liver disease
Tim Hendrikx, Bernd Schnabl
Expert Review of Gastroenterology & Hepatology
|
June 20, 2015
Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?
Katharina Brandl, Bernd Schnabl
Clinical Liver Disease
|
April 10, 2018
Risk factors for progression of and treatment options for NAFLD in children
Phillipp Hartmann, Bernd Schnabl
Methods and Protocols
|
October 26, 2022
Inexpensive, Accurate, and Stable Method to Quantitate Blood Alanine Aminotransferase (ALT) Levels
Phillipp Hartmann, Bernd Schnabl
Liver International : Official Journal of the International Association for the Study of the Liver
|
May 15, 2023
Acute alcohol-associated hepatitis: Latest findings in non-invasive biomarkers and treatment
Tomoo Yamazaki, Bernd Schnabl
JHEP Reports : Innovation in Hepatology
|
November 15, 2023
Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases
Jumpei Fujiki, Bernd Schnabl
Liver International : Official Journal of the International Association for the Study of the Liver
|
January 7, 2022
Roles for the mycobiome in liver disease
Suling Zeng, Bernd Schnabl
Cellular and Molecular Gastroenterology and Hepatology
|
June 20, 2015
The gut microbiota and liver disease
Cristina Llorente, Bernd Schnabl
Seminars in Liver Disease
|
May 6, 2021
New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease
Phillipp Hartmann, Bernd Schnabl
Hepatology (Baltimore, Md.)
|
January 10, 2023
Can a mucosal microbiota signature predict disease severity, survival, and disease recurrence in PSC?
Phillipp Hartmann, Bernd Schnabl
Page
of 29
Search research articles
Search
Showing results (21-30 of 283) with videos related to
Sort By:
Page
of 29
Journal of Gastroenterology
|
November 5, 2018
Antimicrobial proteins: intestinal guards to protect against liver disease
Tim Hendrikx, Bernd Schnabl
Expert Review of Gastroenterology & Hepatology
|
June 20, 2015
Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?
Katharina Brandl, Bernd Schnabl
Clinical Liver Disease
|
April 10, 2018
Risk factors for progression of and treatment options for NAFLD in children
Phillipp Hartmann, Bernd Schnabl
Methods and Protocols
|
October 26, 2022
Inexpensive, Accurate, and Stable Method to Quantitate Blood Alanine Aminotransferase (ALT) Levels
Phillipp Hartmann, Bernd Schnabl
Liver International : Official Journal of the International Association for the Study of the Liver
|
May 15, 2023
Acute alcohol-associated hepatitis: Latest findings in non-invasive biomarkers and treatment
Tomoo Yamazaki, Bernd Schnabl
JHEP Reports : Innovation in Hepatology
|
November 15, 2023
Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases
Jumpei Fujiki, Bernd Schnabl
Liver International : Official Journal of the International Association for the Study of the Liver
|
January 7, 2022
Roles for the mycobiome in liver disease
Suling Zeng, Bernd Schnabl
Cellular and Molecular Gastroenterology and Hepatology
|
June 20, 2015
The gut microbiota and liver disease
Cristina Llorente, Bernd Schnabl
Seminars in Liver Disease
|
May 6, 2021
New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease
Phillipp Hartmann, Bernd Schnabl
Hepatology (Baltimore, Md.)
|
January 10, 2023
Can a mucosal microbiota signature predict disease severity, survival, and disease recurrence in PSC?
Phillipp Hartmann, Bernd Schnabl
Page
of 29